Search and analyze individual stocks with comprehensive metrics
Biogen Pharmachem Industries Inc
Fundamental Score
Biogen Pharmachem Industries Inc Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of BIOGEN across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (51.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
8 factors identified
Below-Average Return on Equity (-0.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.39%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (0.26%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Other Financial Services sector...
Financial Statements
Comprehensive financial data for Biogen Pharmachem Industries Inc
About BIOGEN
Business Overview
Biogen Pharmachem Industries Limited engages in the trading of shares and securities. The company was formerly known as Sun Techno Overseas Limited and changed its name to Biogen Pharmachem Industries Limited in March 2021. Biogen Pharmachem Industries Limited was incorporated in 1995 and is based in Rajkot, India.
Company Details
Key Leadership
Latest News
BIOGEN Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Biogen Pharmachem Industries Inc (BIOGEN)?
As of 16 Jan 2026, 10:14 am IST, Biogen Pharmachem Industries Inc (BIOGEN) is currently trading at ₹0.68. The stock has a market capitalization of ₹68.60 (Cr).
Is BIOGEN share price Overvalued or Undervalued?
BIOGEN is currently trading at a P/E ratio of 39.88x, compared to the industry average of 30.94x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Biogen Pharmachem Industries Inc share price?
Key factors influencing BIOGEN's price include its quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Biogen Pharmachem Industries Inc a good stock for long-term investment?
Biogen Pharmachem Industries Inc shows a 5-year Profit Growth of N/A% and an ROE of -0.39%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Biogen Pharmachem Industries Inc compare with its industry peers?
Biogen Pharmachem Industries Inc competes with major peers in the Other Financial Services. Investors should compare BIOGEN's P/E of 39.88x and ROE of -0.39% against the industry averages to determine its competitive standing.
What is the P/E ratio of BIOGEN and what does it mean?
BIOGEN has a P/E ratio of 39.88x compared to the industry average of 30.94x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹40 for every ₹1 of annual earnings.
How is BIOGEN performing according to Bull Run's analysis?
BIOGEN has a Bull Run fundamental score of 13.5/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does BIOGEN belong to?
BIOGEN operates in the Other Financial Services industry. This classification helps understand the competitive landscape and sector-specific trends affecting Biogen Pharmachem Industries Inc.
What is Return on Equity (ROE) and why is it important for BIOGEN?
BIOGEN has an ROE of -0.39%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Biogen Pharmachem Industries Inc generates profits from shareholders' equity.
How is BIOGEN's debt-to-equity ratio and what does it indicate?
BIOGEN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is BIOGEN's dividend yield and is it a good dividend stock?
BIOGEN offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has BIOGEN grown over the past 5 years?
BIOGEN has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in BIOGEN and why does it matter?
Promoters hold 0.00% of BIOGEN shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is BIOGEN's market capitalization category?
BIOGEN has a market capitalization of ₹69 crores, placing it in the Small-cap category.
How volatile is BIOGEN stock?
BIOGEN has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for BIOGEN?
BIOGEN has a 52-week high of ₹N/A and low of ₹N/A.
What is BIOGEN's operating profit margin trend?
BIOGEN has a 5-year average Operating Profit Margin (OPM) of 0.26%, indicating the company's operational efficiency.
How is BIOGEN's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of N/A% and YoY Profit Growth of 51.00%.
What is the institutional holding pattern in BIOGEN?
BIOGEN has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.